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Abstract    
The sensitization and exposure to fungal allergens have been reported to be associated 
with asthma. The aim of this study was to clarify the impact of sensitization to 
Schizophyllum commune (S. commune) on the severity and exacerbations of asthma.  
Ninety-two patients with asthma of various levels of severity (mild (n=18), moderate 
(28), and severe (46)) and exacerbation severity (moderate (n=43) and severe (6)), were 
retrospectively examined with regard to fungal sensitization such as specific IgE or 
intradermal skin reactions against S. commune and other common allergens. We also 
classified the patients into 3 groups; 1) 3 or more asthma attacks during the past 1 year 
(F-BA) (n=29), 2) one or two asthma attacks (NF-BA) (n=20), and 3) no asthma attack 
(C-BA) (n=43).  
The positive rate of late cutaneous reactions to S. commune was higher in patients with 
severe asthma (41.2%) than moderate (26.1%) and mild asthma (6.7%), and was 
significantly different among the three groups (p<0.05). Though the ratio did not show 
significant difference between the patients having a severe (83.3%) and moderate 
(36.1%) exacerbation, it was higher in F-BA (60.9 %) than in NF-BA (21.1%) and 
C-BA patients (10.0%), and it was significantly different among the three groups 
(p=0.0002). A multivariate analysis identified positive results for late phase skin 
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reactions to S. commune and the age of the patients as an independent determinant of 
asthma severity, and the skin results and %FVC an independent determinant of 
exacerbation frequency.  
This study demonstrated that S. commune is an environmental fungus that appears to 
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Throughout the Global Initiative for Asthma (GINA) Science Committee report in 
2009 [1], emphasis is placed on the concept that the goal of asthma treatment is to 
achieve and maintain clinical control. Each asthmatic patient should be assessed to 
establish their level of asthma control according to the 5 items of clinical manifestations, 
and patients are then assigned to one of five “treatment steps” in accordance with the 
management approach based on the level of asthma control. Furthermore, as assessment 
of future risk, frequent exacerbations in past year are listed as the features that were 
associated with an increased risk of adverse events in the future. Because patients with 
well-controlled asthma are less likely to experience exacerbations than those whose 
asthma is not well-controlled, preventing any exacerbation of asthma is an important 
clinical issue in asthma control.  
It is well-known that fungal exposure is associated with exacerbations. Recently the 
sensitization and exposure to fungal allergens such as Aspergillus, Alternaria, 
Penicillium, Cladosporium and Trichophyton have been reported to be associated with 
asthma exacerbations and severity [2], and the frequency of exacerbations, treatment 
requirements, and admission to intensive care for asthma has been found to be 
associated with skin-test reactivity to one or more fungi [3]. Thus the investigations to 
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identify environmental fungi are considered to be part of initial assessment to enable the 
use of avoidance strategies in asthma management [4]. 
From the results of our series of studies [5, 6] on patients with allergic fungal 
respiratory diseases, we have focused on the possible role of basidiomycetous (BM) 
fungi especially Bjerkandera adusta [7] (B. adusta; the major cause of “allergic fungal 
cough” in Japan) as a fungal aeroallergen [8]. We recently encountered two cases of 
asthma caused by Schizophyllum commune (S. commune, “suehirotake” in Japanese) [9]. 
Although this fungus, one of the BM fungi, is well-known as a causative fungus of 
mucoid impaction of the bronchi (MIB) [10], allergic bronchopulmonary mycosis 
(ABPM) [11,12] and allergic fungal sinusitis (AFS) [13], the influence of the 
sensitization to the fungus in asthmatics has not yet been reported. 
Therefore we compared the allergological findings of the asthmatics and reported 
the impact of sensitization to S. commune on the severity and the exacerbations of 
asthma. 
 
Methods and Materials  
The medical records of 92 patients with asthma referred to Saiseikai Kanazawa Hospital 
between August and October 2009, who had not been treated with maintenance oral 
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corticosteroids, were collected and reviewed retrospectively. In this study, the severity 
of asthma in the patients had been already classified based on their clinical features and 
lung function in accordance with the 2006 GINA guidelines [14]; while the previous 
classification was recommended only for research purposes by GINA 2009. The asthma 
exacerbation severity was classified according to the recent recommended definitions 
provided by the Task Force [15]; wherein “severe exacerbations” were classified as 
events that usually require hospitalization/emergency room (ER) visits and/or the use of 
systemic corticosteroids for at least 3 days (Acute care settings), and “moderate 
exacerbation” as an event that leads to an increase in the need for existing asthma 
therapy not including systemic corticosteroids or a change in asthma symptoms/lung 
function over a period of at least 2 days, not warranting hospital admission (Community 
settings).  
 Because the classification of the frequency of exacerbation has not yet been clearly 
defined, we classified the patients who had experienced exacerbations which required 
intravenous corticosteroid therapies in spite of adequate interval control into 3 groups 
according to the frequency of the episodes as an assessment of exacerbation tendency; 
1) patients who had experienced exacerbations 3 times or more during the past 1 year 
(frequent group; F-BA), 2) patients who had experienced one or two exacerbations 
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(non-frequent group; NF-BA), and 3) the other patients who had never experienced such 
exacerbations (controlled group; C-BA).  
The following information was collected from the medical records of all of the 
patients: name, date of birth, gender, smoking habits, and the results of examinations 
such as blood tests, chest radiographs, and pulmonary function tests. And for the 
measurements of allergic status, the allergological tests such as intradermal skin test and 
serological test had been performed at least 3 months after the latest exacerbation. 
Patients with asthma of each severity, each exacerbation severity, and each exacerbation 
frequency were compared in a cross-sectional manner with regard to gender, age, FEV1, 
and allergological characteristics. 
 This retrospective study was approved by the Institutional Review Board (reference 
number 2009004), and written informed consent was obtained from each of the 92 
patients. 
 
Preparation of the antigenic solution 
Aspergillus, Alternaria, Candida: These antigens were commercially available (Torii 
Pharmacy, Tokyo, Japan).  
B. adusta, S. commune:  One liter of Sabouraud dextrose broth in 3 liter flasks was 
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sterilized. Five mL of a B. adusta (NBRC 4983) or S. commune spore suspension (105 
spores per mL) in sterile physiological saline from 14-day-old Sabouraud dextrose agar 
culture were used to inoculate the flask. The flask was shaken at 150 rpm in a 25°C 
rotary shaker incubator for 14 days. Mycelia were separated by filtration and 




Intradermal skin test 
An antigenic solution (polysaccharide) was injected intradermally with a tuberculin 
syringe (0.02 mL, 1 mg/mL) to assess the skin response to the solution. The results were 
judged to be positive when the longer axis of the flare exceeded 9 mm at 15 minutes 
(Immediate phase), and 10 mm at 8 hrs (late phase) after the injection.  
The results of the late skin test were checked and recorded by each patient at 8 hours 
after the tests. The next day, we telephoned the patients and completed the examination. 
 
Serological test 
House-dust, Mite, Aspergillus, Alternaria, Penicillium, Cladosporium, Candida 
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Trichophyton: Allergen-specific IgE antibodies were detected with a capsulated 
hydrophilic carrier polymer radioallergosorbent test fluoroenzyme immunoassay 
(Phadia, Uppsala, Sweden) at an external laboratory (SRL, Tokyo, Japan) 
Schizophyllum commune: The Phadia (previously Pharmacia) CAP system was used to 
quantify specific IgE levels (Phadia Ltd, Uppsala, Sweden) [16]. A positive test was 
taken as a measurement > 0.35 units of allergen (UA)/mL. 
 
Statistical analysis 
Variables are expressed as the mean (SD) unless otherwise stated. For comparison 
of multiple groups, analysis of variance (ANOVA) followed by Fisher protected 
least significant difference post hoc test was used for parametric data, when 
significant difference was found. For nonparametric data, the Kruskal-Wallis test 
followed by the Mann-Whitney U test was applied instead. The χ2 test was used for 
categorical data. Logistic regression analysis was performed to test for independent 
effects of age, smoking habit, lung functions, and positive late phase skin reactions 
against S. commune on asthma severity and exacerbation severity. A multiple 
regression analysis was performed on exacerbation frequency. Analyses were 
performed by using a statistical software package (StatView; SAS Institute Inc; 
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Cary, NC). A p value of < 0.05 was considered statistically significant. 
 
Results 
The clinical records of the 92 asthmatics were gathered and analyzed. Chest and sinus 
radiographs were normal in all patients. The results of the late phase positive skin 
reaction tests were obtained from 57, 72, and 57 patients for Aspergillus, S. commune, 
and B. adusta, respectively.    
Analysis for asthma severity (Table.1) 
Table 1 shows the characteristics and results of the three groups of asthma severity. 
Patients with mild and moderate severities of asthma were significantly younger than 
the patients with severe asthma. The smoking habits did not differ among the groups. 
The FVC (% predicted), FEV1 (% predicted) and the FEV1/FVC ratio (%) in mild and 
moderate asthmatics were significantly higher than those in severe asthmatics (p < 0.05, 
p < 0.01, and p < 0.01, respectively). The total IgE levels and the positive rate for a 
specific IgE did not differ among these groups.  
The positive skin reaction rates did not differ among these groups except for the late 
phase skin reaction against S. commune (p < 0.05). The results of an investigation of the 
serum S. commune-specific IgE levels were available for 12 patients, and the value was 
 12
not elevated in any of them. 
A multiple logistic regression analysis was performed by including age and the late 
phase skin reaction against S. commune as possible predictors of asthma severity. The 
probability of severe vs mild and moderate asthma was found to be significantly 
associated with age and positive late phase skin reaction against S. commune (Table.4).  
Analysis for exacerbation severity (Table.2) 
In this analysis, 43 patients who had never experienced any exacerbations were 
excluded. Table 2 shows the characteristics and results of two groups divided by their 
exacerbation severity. Gender and age were well matched within the each group. 
Current smoker showed predominance in the severe exacerbation group. The FVC (% 
predicted) and FEV1 (% predicted) in the moderate exacerbation group were 
significantly higher than those in the severe exacerbation group. 
 The number of patients from whom we had obtained the results of the late phase 
positive skin reaction tests for each fungus was shown in Table 2.  The positive of the 
late phase skin reaction against S. commune (83.3%) was significantly higher in the 
severe exacerbation group than in the moderate exacerbation group (p < 0.01). 
A multiple logistic regression analysis was performed by including smoking habits, 
lung functions, and the late phase skin reaction against S. commune as possible 
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predictors of exacerbation severity. The probability of the severe vs moderate 
exacerbation was not demonstrated in this analysis (Table 4).  
 
Analysis for exacerbation frequency (Table.3) 
Table 3 shows the characteristics and results of three groups divided based on their 
exacerbation frequency. The age distribution, the gender of the population, and smoking 
habits did not differ significantly among three groups. The FVC (% predicted) and 
FEV1/FVC ratio (%) in the C-BA and NF-BA groups were significantly higher than 
those in the F-BA group (p < 0.05, and p < 0.01, respectively). The total IgE levels and 
the rate of positive specific IgE did not differ significantly among the 3 groups. The rate 
of positive skin reactions did not differ among these groups except for the late phase 
skin reaction against S. commune (p < 0.001). Because the %FVC and late skin reaction 
against S. commune were adopted as possible predictors of the exacerbation frequency 
according to a stepwise analysis among the 3 items, thereafter multiple logistic analyses 
were performed by including the two variables except FEV1/FVC ratio (%). The 
probability of asthma exacerbation frequency was found to be significantly associated 
with %FVC and positive late phase skin reaction against S. commune (p < 0.0001) on the 




Bronchial asthma is a chronic inflammatory disease of the airways, which may worsen 
due to numerous extrinsic factors such as continuous exposure to fungal agents. The 
factors that influence the risk of asthma have been divided into those that cause the 
development of asthma and those that trigger asthma symptoms. It is known that fungi 
involved in outdoor allergens are important as environmental factors, and our recent 
studies suggested that S. commune is an important candidate organism acting as a 
causative fungal antigen of bronchial asthma [9] similar to Trichophyton species [17-20]. 
Therefore, we retrospectively examined whether an environmental fungus such as S. 
commune could enhance the clinical expression of asthma. 
Asthma severity has recently been classified on the basis of the intensity of 
treatment required to achieve good asthma control in subjects with “mild asthma” and 
“severe asthma”. The patient’s asthma severity will be established based on a 
combination of their current level of symptoms and their current maintenance treatment 
step in future studies; however, in this retrospective study, the severity of all asthmatics 
had been classified based on their daily medication regimen and response to treatment, 
as described in the GINA 2006 guidelines for research purposes [1]. Matsuoka et al. 
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reported a strong association of the allergen with the severity of asthma and the 
establishment of sensitization using serum radioallergosorbent assays for IgE antibodies 
to Trichophyton [19], in contrast to their report, our present results demonstrated no 
association of serum specific-IgE antibodies to Trichophyton with the severity of 
asthma. The presence of Trichophyton infection has been suggested to be an important 
determinant of sensitization to Trichophyton; however in our study, there were no 
significant differences in the frequencies of fungal skin infections among the asthma 
severities. Therefore, it is impossible that fungal skin infections may affect the detection 
frequency of specific IgE against Trichophyton in our study. The present study revealed 
that there were no significant differences in the positive results for the immediate and 
late cutaneous reactions to 3 well-known environmental fungi (Aspergillus, Alternaria, 
and Candida) among the asthma severities [21]. The reason for this result is unclear, but 
it might be related to geographic differences in the frequency of sensitization.  
Asthma exacerbations are considered to be caused by a variety of factors, such as 
allergens, viral infections, pollutants, drugs, and also fungi. Therefore, reducing a 
patient’s exposure to risk factors will improve the control of their asthma and reduce 
their need for medication [22]. Each patient was assigned to one of five treatment steps 
depending on their current level of control, and treatment was adjusted in a continuous 
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cycle which involved: assessing asthma control, treating to achieve control, monitoring 
to maintain control, and by changes in their asthma control status. Because asthma is a 
variable disease, treatment had to be adjusted periodically in response to loss of control, 
as indicated by either worsening symptoms or the development of exacerbation. Most 
recently, an American Thoracic Society (ATS)/European Respiratory Society (ERS) 
consensus report aimed to standardize the definitions of exacerbations for clinical trials, 
and defined as a “severe exacerbation” and “moderate exacerbation” [15]. Our current 
study revealed a significant difference in the smoking habit, lung function, and the rate 
of positive late phase skin reactions against S. commune, but the probability of the 
severe vs moderate exacerbation was not demonstrated based on a multiple regression 
analysis, thus suggesting that many other factors may be associated with the variability 
in the severity of exacerbation.  
In the GINA 2009, a history of frequent exacerbations in the past year was 
emphasized from the aspect of assessment of future risk, and was listed as one of the 
features that were associated with an increased risk of adverse events in the future. The 
severity of the each event of the asthma attack, which reflects exacerbation rather than 
just transient loss of asthma control, may be affected by the magnitude of the response 
against viral infection or by the some other factors, such as physical condition or severe 
 17
weather. We therefore assumed that the so-called “exacerbation tendency” of asthma 
was represented by the frequency of exacerbations rather than by the severity of each 
exacerbation. 
A multivariate analysis identified positive results for late phase skin reactions to S. 
commune and age of the patients as an independent determinant of asthma severity, and 
the skin results and %FVC as that of exacerbation frequency, but such a trend was not 
found for other allergens such as house-dust, Aspergillus, Alternaria, Penicillium, and 
Cladosporium [23]. 
There is emerging evidence that the innate immune response in asthma is impaired, 
airway inflammation may modulate the response to triggers and genetic polymorphisms 
may confer an increased risk of exacerbations [24]. Because it has been already 
suggested that the presence of eosinophilic inflammation in the bronchial wall promotes 
the development of an exacerbation in combination with a viral infection, a clinical 
research study concerning the eosinophil response in the bronchial wall to S. commune 
or to the secretory products of this fungus will also be important to elucidate the 
mechanisms underlying the exacerbation of asthma in the future. 
From the results of the present study, S. commune, a BM fungus, is considered to 
be one of the environmental fungi which have a potential role in enhancing the severity 
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of asthma and asthma exacerbation via sensitization to the fungus. S. commune 
colonizes rotting wood, and it is distributed throughout the world. Therefore, not only 
pharmacologic intervention [25, 26] but also careful environmental management [12] 
may positively help to prevent the development of asthma, asthma symptoms, and 
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Table 1 Characteristics and results of three groups of asthma severity 
Table 2 Characteristics and results of two groups of asthma exacerbation severity 
Table 3 Characteristics and results of three groups of asthma exacerbation frequency 
Table 4 Results of multiple logistic regression analysis 
 
The analysis was performed by including age, Trichophyton-specific IgE, and the late 
phase skin reaction against S. commune as possible predictors of the severity and 
exacerbation of asthma.  
 
 
Table 1 The characteristics and results of three groups of asthma severity 
  Asthma severity   
Characteristics Mild Moderate Severe p Value 
Patients, No 18 28 46  
Gender, M/F (F %) 6 / 12 (66.7) 17 / 11 (39.3) 27 / 19 (41.3) NS 
Age, yr 54.7 ± 15.2 56.5 ± 15.8 64.9 ± 12.1 p < 0.01 
Smoking habit (never, ex, current) 16 / 1 / 1 24 / 1 / 3 33 / 6 / 7 NS 
FVC, % predicted 114.9 ± 14.2 113.6 ± 18.2 100.8 ± 25.7 p < 0.05 
FEV1, % predicted 108.6 ± 5.4 105.8 ± 4.3 91.4 ± 3.4 p < 0.01 
FEV1 / FVC ratio (%) 79.0 ± 9.1 76.0 ± 9.9 65.3 ± 17.5 p < 0.01 
IgE, IU / ml 262.0 ± 222.7 301.8 ± 178.6 611.2 ± 140.9 NS 
     
Positive specific IgE     
   House-dust  9 (50) 11 (39.3) 14 (30.4) NS 
   Mite 8 (44.4) 7 (25.0) 14 (30.4) NS 
   Aspergillus 1 (5.6) 2 (7.1) 4 (8.7) NS 
   Alternaria 0 (0) 1 (3.6) 2 (4.4) NS 
   Penicillium  0 (0) 2 (7.1) 4 (8.7) NS 
   Candida 2 (11.1) 2 (7.1) 13 (28.3) NS 
   Trichophyton  1 (5.6) 3 (10.7) 5 (10.9) NS 
   S. commune  0 / 1 (0) 0 / 4 (0) 0 / 7 (0) NS 
     
Positive skin reaction     
   Aspergillus     Immediate 1 (5.6) 4 (14.3) 6 (13.0) NS 
                    Late 1 / 11 (9.1) 2 / 21 (9.5) 3 / 25 (12.0) NS 
   S. commune     Immediate 1 (5.6) 6 (21.4) 13 (28.3) NS 
                   Late 1 / 15 (6.7) 6 / 23 (26.1) 14 / 34 (41.2) p < 0.05 
   B. adusta       Immediate 0 (0) 2 (7.1) 6 (13.4) NS 
                    Late 5 / 13 (38.5) 5 / 19 (26.3) 9 / 25 (36.0) NS 
   Alternalia       Immediate 1(5.9) 2 (7.1) 1 (2.2) NS 
   Candida        Immediate 10 (58.8) 16 (57.1) 30 (65.2) NS 
     
Skin fungal infection 7 (38.9) 14 (50.0) 15 (32.6) NS 
HbA1c 5.3 ± 0.8 5.2 ± 1.2 5.5 ± 0.7 NS 
 
Table 2 The characteristics and results of two groups of asthma exacerbation severity 
 Exacerbation severity  
Characteristics Moderate Severe p Value 
Patients, No 43 6  
Gender, M/F (F %) 20 / 23 (53.5) 5 / 1 (16.7) NS 
Age, yr 62.8 ± 13.6 67 ± 10.2 NS 
Smoking habit (never, ex, current) 34 / 5 / 4 2 / 1 / 3  p < 0.01 
FVC, % predicted 108.3 ± 17.4 81.7 ± 29.8 p < 0.05 
FEV1, % predicted 98.4 ± 23.6 63.5 ± 34.3 p < 0.05 
FEV1 / FVC ratio (%) 70.2 ± 14.0 55.6 ± 18.1 NS 
IgE, IU / ml 365.9 ± 596.5 1792.2 ± 3095.3 NS 
    
Positive specific IgE     
   House-dust  13 (30.2) 2 (33.3) NS 
   Mite 13 (30.2) 2 (33.3) NS 
   Aspergillus 2 (4.7) 1 (16.7) NS 
   Alternaria 1 (2.3) 1 (16.7) NS 
   Penicillium 2 (4.7) 1 (16.7) NS 
   Candida 10 (23.3) 3 (50.0) NS 
   Trichophyton  2 (4.7) 1 (16.7) NS 
   S. commune  0 / 6 (0) 0 / 2 (0) NS 
    
Positive skin reaction    
   Aspergillus     Ｉmmediate 2 (4.7) 1 (16.7) NS 
                   Late 2 / 28 (7.1) 1 / 4 (25.0) NS 
   S. commune     Immediate 8 (18.6) 3 (50.0) NS 
                    Late 13 / 36 (36.1) 5 / 6 (83.3） p < 0.05 
   B. adusta       Immediate 5 (11.6) 0 (0) NS 
                    Late 10 / 28 (35.7) 2 / 4 (50.0) NS 
   Alternalia       Immediate 1 (2.3) 0 (0) NS 
   Candida        Immediate 29 (67.4)  4 (66.7) NS 
    
Skin fungal infection 15 (34.9) 3 (50.0) NS 
HbA1c 5.6 ± 0.9 5.3 ± 0.3 NS 
 
Table 3 The characteristics and results of three groups of asthma exacerbation frequency 
  Exacerbation frequency   
Characteristics Controlled Non-frequent Frequent p Value 
Patients, No 43 20 29  
Gender, M/F (F %) 25 / 18 (41.9) 9 / 11 (55.0) 16 / 13 (44.8) NS 
Age, yr 56.9 ± 15.3 62.0 ± 14.6 64.3 ± 12.3 NS 
Smoking habit (never, ex, current) 37 / 2 / 4 17 / 1 / 2 19 / 5 / 5 NS 
FVC, % predicted 112.9 ± 17.8 110.5 ± 16.0 97.2 ± 29.0 p < 0.05 
FEV1, % predicted 104.1 ± 18.2 100.7 ± 19.0 90.8 ± 32.0 NS 
FEV1 / FVC ratio (%) 75.5 ± 10.7 72.2 ± 13.3 64.3 ± 19.6 p<0.01 
IgE, IU / ml 331.0 ± 396.4 318.4 ± 724.0 703.1 ± 1490.2 NS 
     
Positive specific IgE      
   House-dust  19 (44.2) 5 (25.0) 10 (34.5) NS 
   Mite 14 (32.6) 5 (25.0) 10 (34.5) NS 
   Aspergillus 4 (9.3) 1 (5.0) 2 (6.9) NS 
   Alternaria 1 (2.3) 1 (5.0) 1 (3.45) NS 
   Penicillium 3 (7.0) 1 (5.0) 2 (6.9) NS 
   Candida 4 (9.3) 4 (20.0) 9 (31.0) NS 
   Trichophyton  6 (14.0) 1 (5.0) 2 (6.9) NS 
   S. commune  0 / 4 (0) 0 / 0 (0) 0 / 8 (0) NS 
     
Positive skin reaction     
   Aspergillus     Immediate 8 (18.6) 0 (0) 3 (10.3) NS 
                    Late 3 / 25 (12.0) 0 / 15 (0) 3 / 17 (17.7) NS 
   S. commune    Immediate 9 (21.0) 5 (25.0) 6 (21.0) NS 
                    Late 3 / 30 (10.0) 4 / 19 (21.1) 14 / 23 (60.9) p<0.001 
   B. adusta        Immediate 3 (7.0) 3 (15.0) 2 (6.9) NS 
                    Late 7 / 25 (28.0) 4 / 17 (23.5) 8 / 15 (53.3) NS 
   Alternalia       Immediate 3 (7.1) 1 (5.0) 0 (0) NS 
   Candida        Immediate 23 (54.8) 11 (55.0) 22 (75.9) NS 
     
Skin fungal infection 18 (41.9) 8 (40.0) 10 (34.5) NS 
HbA1c 5.1 ± 0.9 5.5 ± 0.9 5.6 ± 0.8 NS 
 
Table 4  Results of multiple logistic regression analysis 
Asthma severity     
      Severe vs. moderate and mild asthma
Variables  OR 95%CI p Value 
Age  1.04 1.00-1.08 p < 0.05 
Positive late skin reaction against S. commune  1.82 1.06-3.24 p < 0.05 
     
     
Exacerbation severity     
       Severe vs. moderate exacerbation  
Variables  OR 95%CI p Value 
Smoking habit  8.53 0.84-14.50 0.11 
FEV1, % predicted  0.01 0.91-1.00 0.08 
Positive late skin reaction against S. commune  9.63 0.93-18.17 0.11 
     
     
Exacerbation frequency     




Variables  PRC β p Value 
%FVC  -0.01 -0.23 p < 0.05 
Positive late skin reaction against S. commune  0.41 0.43 p < 0.0001
CI: cofidence interval; OR: odds ratio 
PRC: partial regression coefficient 
 
The analysis was performed by including age, Trichophyton-specific IgE, and the late 
phase skin reaction against S. commune as possible predictors of the severity and 
exacerbation of asthma.  
 
 
 
